 <h1>Neupogen Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>filgrastim</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about filgrastim. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Neupogen.</p><h2>In Summary</h2><p><b>Common side effects of Neupogen include:</b> hyperuricemia, increased lactate dehydrogenase, increased leukocyte alkaline phosphatase, increased serum alkaline phosphatase, ostealgia, and thrombocytopenia. <b>Other side effects include:</b> arthralgia, headache, myalgia, and pruritus.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to filgrastim: injection solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, filgrastim (the active ingredient contained in Neupogen) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking filgrastim:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding gums</li>
<li>bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>blood in the urine or stools</li>
<li>bloody nose</li>
<li>chills</li>
<li>cough</li>
<li>coughing up blood</li>
<li>diarrhea</li>
<li>difficult or labored breathing</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>facial swelling</li>
<li>feeling of fullness</li>
<li>fever</li>
<li>headache</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>nosebleeds</li>
<li>pain in the back, ribs, arms, or legs</li>
<li>pain spreading to the left shoulder</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>paralysis</li>
<li>pinpoint red or purple spots on the skin</li>
<li>prolonged bleeding from cuts</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>skin rash</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips, tongue, or inside the mouth</li>
<li>stomach pain</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>chest pain</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blisters on the skin</li>
<li>blue lips, fingernails, or skin</li>
<li>difficult or fast breathing</li>
<li>sores on the skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of filgrastim may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bone, joint, or muscle pain</li>
<li>hair loss or thinning of the hair</li>
<li>loss of appetite</li>
<li>weight loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Cracked lips</li>
<li>difficulty having a bowel movement</li>
<li>swelling or inflammation of the mouth</li>
</ul><p>
<!-- end injection solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to filgrastim: injectable solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased platelet counts (up to 97%), increase in white blood cell counts between 10 x 10(9)/L and 70 x 10(9)/L (up to 88%), decreased hemoglobin (up to 65%), mild to moderate decreases in hemoglobin (up to 59%), leukocytosis (up to 41%), thrombocytopenia (up to 38%), transient thrombocytopenia (up to 35%), palpable splenomegaly (up to 30%), splenomegaly (up to 30%), anemia (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Spleen disorder, splenic rupture/fatal splenic rupture</p>
<p><b>Uncommon</b> (0.1% to 1%): Sickle cell anemia with crisis/sickle cell crisis</p>
<p><b>Rare</b> (0.01% to 0.1%): Cytopenia</p>
<p><b>Postmarketing reports</b>: Sickle cell disorders<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Mild to moderate musculoskeletal symptoms (up to 44%), medullary bone pain (up to 38%), mild to moderate bone pain (up to 33%), bone pain (up to 30%), back pain (up to 15%), musculoskeletal pain (up to 14%), flank pain (up to 12%), myalgia (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Arthralgia, extremity pain, muscle spasms, osteoporosis, severe musculoskeletal pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Pseudogout/chondrocalcinosis pyrophosphate, rheumatoid arthritis exacerbation</p>
<p><b>Rare</b> (0.01% to 0.1%): Decreased bone density</p>
<p><b>Frequency not reported</b>: Musculoskeletal chest pain, neck pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (up to 48%), fatigue (up to 20%), pain (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Asthenia, generalized weakness, malaise, mucosal inflammation, mucositis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (up to 15%), cough (up to 14%), dyspnea (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Bronchitis, hemoptysis, sore throat, upper respiratory tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute respiratory distress syndrome (ARDS), hypoxia, interstitial lung disease, pulmonary edema, pulmonary hemorrhage, pulmonary infiltrates/lung infiltration, respiratory failure</p>
<p><b>Very rare</b> (less than 0.01%): Pulmonary adverse events</p>
<p><b>Frequency not reported</b>: Interstitial pneumonia, serious pulmonary adverse events</p>
<p><b>Postmarketing reports</b>: Alveolar hemorrhage<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Spontaneously reversible elevations in lactate dehydrogenase (up to 56%), spontaneously reversible elevations in uric acid (up to 56%)</p>
<p><b>Common</b> (1% to 10%): Anorexia, blood glucose decreased, blood lactate dehydrogenase increased, blood uric acid increased, decreased appetite, hyperuricemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Fluid volume disturbances<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Spontaneously reversible elevations in alkaline phosphatase (up to 56%), blood alkaline phosphatase increased (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Gamma glutamyltransferase increased, hepatomegaly</p>
<p><b>Uncommon</b> (0.1% to 1%): AST increased<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 43%), abdominal pain (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Constipation, diarrhea, oral pain, oropharyngeal pain, pharyngolaryngeal pain, vomiting</p>
<p><b>Frequency not reported</b>: Stomatitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (up to 14%), headache (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Hypoesthesia, paresthesia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash/skin rash (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Alopecia, cutaneous/leukocytoclastic vasculitis, erythema</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute febrile neutrophilic dermatosis/Sweet's syndrome, maculopapular rash, pre-existing skin disorder exacerbation, psoriasis exacerbation</p>
<p><b>Frequency not reported</b>: Urticaria<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Chest pain (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Hypertension, hypotension, peripheral edema</p>
<p><b>Uncommon</b> (0.1% to 1%): Capillary leak syndrome, veno-occlusive disease</p>
<p><b>Rare</b> (0.01% to 0.1%): Aortitis, vascular disorder<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysuria, hematuria, urinary tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Proteinuria,</p>
<p><b>Rare</b> (0.01% to 0.1%): Urine abnormality<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain, injection site reaction, transfusion reaction<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Antibody formation, sepsis</p>
<p><b>Uncommon</b> (0.1% to 1%): Graft versus Host Disease (GvHD)/fatal GvHD<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity</p>
<p><b>Uncommon</b> (0.1% to 1%): Anaphylactic reaction, hypersensitivity/hypersensitivity reactions, severe allergic reaction</p>
<p><b>Very rare</b> (less than 0.01%): Allergic reaction</p>
<p><b>Frequency not reported</b>: Anaphylaxis, angioedema<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Glomerulonephritis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: cytogenetic abnormalities, transformation to myelodysplastic syndromes (MDS), transformation to acute myeloid leukemia (AML)<sup>[Ref]</sup></p><p>Transformation to MDS/AML and cytogenetic abnormalities appeared to be confined to patients with congenital neutropenia.  The cumulative risk in this population in the eighth year of treatment was predicted to be 16.5%, or approximately 2% per year.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Nivestym (filgrastim)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><p id="ref_2">2. "Product Information. Zarxio (filgrastim)." Sandoz Inc, Broomfield, CO. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. "Product Information. Neupogen (filgrastim)." Amgen, Thousand Oaks, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How many biosimilars have been approved in the United States?</li>
<li>What is the difference between Nivestym and Neupogen?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Neupogen (filgrastim)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>2 Reviews</li>
<li>Drug class: colony stimulating factors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Neupogen &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Zarxio, Nivestym</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Neutropenia Associated with Chemotherapy</li>
<li>Neutropenia</li>
<li>Neutropenia Associated with Radiation</li>
<li>Peripheral Progenitor Cell Transplantation</li>
<li>Bone Marrow Transplantation</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to filgrastim: injectable solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased platelet counts (up to 97%), increase in white blood cell counts between 10 x 10(9)/L and 70 x 10(9)/L (up to 88%), decreased hemoglobin (up to 65%), mild to moderate decreases in hemoglobin (up to 59%), leukocytosis (up to 41%), thrombocytopenia (up to 38%), transient thrombocytopenia (up to 35%), palpable splenomegaly (up to 30%), splenomegaly (up to 30%), anemia (up to 10%)</p><p><b>Common</b> (1% to 10%): Spleen disorder, splenic rupture/fatal splenic rupture</p><p><b>Uncommon</b> (0.1% to 1%): Sickle cell anemia with crisis/sickle cell crisis</p><p><b>Rare</b> (0.01% to 0.1%): Cytopenia</p><p><b>Postmarketing reports</b>: Sickle cell disorders<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Mild to moderate musculoskeletal symptoms (up to 44%), medullary bone pain (up to 38%), mild to moderate bone pain (up to 33%), bone pain (up to 30%), back pain (up to 15%), musculoskeletal pain (up to 14%), flank pain (up to 12%), myalgia (up to 12%)</p><p><b>Common</b> (1% to 10%): Arthralgia, extremity pain, muscle spasms, osteoporosis, severe musculoskeletal pain</p><p><b>Uncommon</b> (0.1% to 1%): Pseudogout/chondrocalcinosis pyrophosphate, rheumatoid arthritis exacerbation</p><p><b>Rare</b> (0.01% to 0.1%): Decreased bone density</p><p><b>Frequency not reported</b>: Musculoskeletal chest pain, neck pain<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (up to 48%), fatigue (up to 20%), pain (up to 12%)</p><p><b>Common</b> (1% to 10%): Asthenia, generalized weakness, malaise, mucosal inflammation, mucositis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (up to 15%), cough (up to 14%), dyspnea (up to 13%)</p><p><b>Common</b> (1% to 10%): Bronchitis, hemoptysis, sore throat, upper respiratory tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Acute respiratory distress syndrome (ARDS), hypoxia, interstitial lung disease, pulmonary edema, pulmonary hemorrhage, pulmonary infiltrates/lung infiltration, respiratory failure</p><p><b>Very rare</b> (less than 0.01%): Pulmonary adverse events</p><p><b>Frequency not reported</b>: Interstitial pneumonia, serious pulmonary adverse events</p><p><b>Postmarketing reports</b>: Alveolar hemorrhage<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Spontaneously reversible elevations in lactate dehydrogenase (up to 56%), spontaneously reversible elevations in uric acid (up to 56%)</p><p><b>Common</b> (1% to 10%): Anorexia, blood glucose decreased, blood lactate dehydrogenase increased, blood uric acid increased, decreased appetite, hyperuricemia</p><p><b>Uncommon</b> (0.1% to 1%): Fluid volume disturbances<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Spontaneously reversible elevations in alkaline phosphatase (up to 56%), blood alkaline phosphatase increased (up to 11%)</p><p><b>Common</b> (1% to 10%): Gamma glutamyltransferase increased, hepatomegaly</p><p><b>Uncommon</b> (0.1% to 1%): AST increased<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 43%), abdominal pain (up to 12%)</p><p><b>Common</b> (1% to 10%): Constipation, diarrhea, oral pain, oropharyngeal pain, pharyngolaryngeal pain, vomiting</p><p><b>Frequency not reported</b>: Stomatitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (up to 14%), headache (up to 10%)</p><p><b>Common</b> (1% to 10%): Hypoesthesia, paresthesia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash/skin rash (up to 14%)</p><p><b>Common</b> (1% to 10%): Alopecia, cutaneous/leukocytoclastic vasculitis, erythema</p><p><b>Uncommon</b> (0.1% to 1%): Acute febrile neutrophilic dermatosis/Sweet's syndrome, maculopapular rash, pre-existing skin disorder exacerbation, psoriasis exacerbation</p><p><b>Frequency not reported</b>: Urticaria<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Chest pain (up to 13%)</p><p><b>Common</b> (1% to 10%): Hypertension, hypotension, peripheral edema</p><p><b>Uncommon</b> (0.1% to 1%): Capillary leak syndrome, veno-occlusive disease</p><p><b>Rare</b> (0.01% to 0.1%): Aortitis, vascular disorder<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysuria, hematuria, urinary tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Proteinuria,</p><p><b>Rare</b> (0.01% to 0.1%): Urine abnormality<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain, injection site reaction, transfusion reaction<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Antibody formation, sepsis</p><p><b>Uncommon</b> (0.1% to 1%): Graft versus Host Disease (GvHD)/fatal GvHD<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity</p><p><b>Uncommon</b> (0.1% to 1%): Anaphylactic reaction, hypersensitivity/hypersensitivity reactions, severe allergic reaction</p><p><b>Very rare</b> (less than 0.01%): Allergic reaction</p><p><b>Frequency not reported</b>: Anaphylaxis, angioedema<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Glomerulonephritis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: cytogenetic abnormalities, transformation to myelodysplastic syndromes (MDS), transformation to acute myeloid leukemia (AML)<sup>[Ref]</sup></p><p>Transformation to MDS/AML and cytogenetic abnormalities appeared to be confined to patients with congenital neutropenia.  The cumulative risk in this population in the eighth year of treatment was predicted to be 16.5%, or approximately 2% per year.<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Nivestym (filgrastim)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><p id="ref_2">2. "Product Information. Zarxio (filgrastim)." Sandoz Inc, Broomfield, CO. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. "Product Information. Neupogen (filgrastim)." Amgen, Thousand Oaks, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How many biosimilars have been approved in the United States?</li>
<li>What is the difference between Nivestym and Neupogen?</li>
</ul><h2>More about Neupogen (filgrastim)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>2 Reviews</li>
<li>Drug class: colony stimulating factors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Neupogen &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Neutropenia Associated with Chemotherapy</li>
<li>Neutropenia</li>
<li>Neutropenia Associated with Radiation</li>
<li>Peripheral Progenitor Cell Transplantation</li>
<li>Bone Marrow Transplantation</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>